The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Phase 2b Data, Phase 3 Trial Design Provide New Insight into Atacicept in IgAN
November 4th 2023Data from multiple presentations at ASN Kidney Week 2023 offer insight into the effects of atacicept in patients with IgA nephropathy as well as the design of the phase 3 trial, which is currently enrolling.
Study Indicates When Geographic Atrophy Will Reach Fovea
November 3rd 2023Without treatment, lesions > 500 µm away from the fovea will take anywhere from 3.07 years to 12.9 years to reach it. With pegcetacoplan treatment, the lesion will reach the fovea anywhere between 3.56 years – 15 years for monthly treatment and 3.47-14.6 years for treatment every other month.
Multicomponent Intervention Fails to Improve Access to Kidney Transplantation
November 3rd 2023EnAKT LKD was conducted across 26 CKD programs in Ontario Canada, offering a multi-component intervention designed to target several barriers thought to prevent kidney transplantation and living donation - however, results showed no significant difference between the intervention and usual care groups.
Urate-Lowering Therapy Could Also Lower Blood Pressure in Gout Patients
November 2nd 2023An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.
ENVISION Trial: Sibeprenlimab Reduces 24-Hour UACR in IgA Nephropathy
November 2nd 2023Presented at ASN Kidney Week 2023, results of the ENVISION trial provide the latest insight into effects of sibeprenlimab in management of IgA nephropathy as the nephrology community awaits the results of its ongoing phase 3 trial.